News articles about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 47.8730095375359 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Spectrum Pharmaceuticals, Inc. (SPPI) projected to achieve -20.20% earnings growth for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Analysts Sights: Spectrum Pharma Inc (SPPI) – Emn News (emnnews.com)
- Here’s Why Spectrum Pharmaceuticals, Inc. Is Slipping Today – Motley Fool (fool.com)
- Jefferies Group Weighs in on Spectrum Pharmaceuticals, Inc.’s Q1 2018 Earnings (SPPI) (americanbankingnews.com)
- Spectrum Pharmaceuticals, Inc. to Post Q1 2018 Earnings of ($0.31) Per Share, B. Riley Forecasts (SPPI) (americanbankingnews.com)
A number of research analysts have recently commented on SPPI shares. BidaskClub cut shares of Spectrum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 22nd. Zacks Investment Research cut shares of Spectrum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. HC Wainwright restated a “buy” rating and issued a $29.00 price target on shares of Spectrum Pharmaceuticals in a report on Monday, December 18th. Finally, B. Riley started coverage on shares of Spectrum Pharmaceuticals in a report on Monday, December 18th. They issued a “buy” rating and a $26.00 price target on the stock. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Spectrum Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $22.83.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last posted its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.04). The company had revenue of $28.57 million during the quarter, compared to the consensus estimate of $33.18 million. Spectrum Pharmaceuticals had a negative return on equity of 30.68% and a negative net margin of 70.66%. The company’s revenue for the quarter was down 18.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.10) earnings per share. research analysts predict that Spectrum Pharmaceuticals will post -0.89 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3252615/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-spectrum-pharmaceuticals-sppi-share-price.html.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.